The diagnostic efficacy of circCDR1as was evaluated in GC patients, recording an AUC of 0.536, which increased to 0.786 when combined with serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19–19 (CA19-9). This evidence concerns the gene CEACAM5 and gastric cancer.